{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002329","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.819710+00:00","generated_at":"2026-05-27T04:31:25.785951+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CervoMed reports no difference between neflamapimod and placebo in DLB trial; OLE data expected Q1 2025","bullets":["No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.","Measured trough plasma concentrations similar to 40mg BID in prior Alzheimer's study, lower than targeted.","Retrospective analysis suggests lower bioavailability related to age of drug batch used in double-blind phase.","PK data from food-effect study and within-subject comparison (13 participants) indicate newer capsules achieved target concentrations.","Topline data from first 16 weeks of open-label extension (OLE) phase expected in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002329","json":"https://secwatch.observer/filing/0001437749-25-002329.json","markdown":"https://secwatch.observer/filing/0001437749-25-002329.md","text":"https://secwatch.observer/filing/0001437749-25-002329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/0001437749-25-002329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/crvo20250130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:31:25.785951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}